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Abstract
Background & Aims—Gastrointestinal (GI) diseases account for substantial morbidity,
mortality and cost. Statistical analyses of the most recent data are necessary to guide GI research,
education and clinical practice. We estimate the burden of GI disease in the US.
Methods—We collected information on the epidemiology of GI diseases (including cancers) and
symptoms, along with data on resource utilization, quality of life, impairments to work and
activity, morbidity, and mortality. These data were obtained from the National Ambulatory
Medical Care Survey; National Health and Wellness Survey; Nationwide Inpatient Sample;
Surveillance, Epidemiology, and End Results Program; National Vital Statistics System;
Thompson Reuters MarketScan®; Medicare; Medicaid; and the Clinical Outcomes Research
Initiative’s National Endoscopic Database. We estimated endoscopic use and costs and examined
trends in endoscopic procedure.
Results—Abdominal pain was the most common gastrointestinal symptom that prompted a
clinic visit (15.9 million visits). Gastroesophageal reflux was the most common GI diagnosis (8.9
million visits). Hospitalizations and mortality from Clostridium difficile infection have doubled in
the last 10 years. Acute pancreatitis was the most common reason for hospitalization (274,119
discharges). Colorectal cancer accounted for more than half of all GI cancers and was the leading
cause of GI-related mortality (52,394 deaths). There were 6.9 million upper, 11.5 million lower,
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and 228,000 biliary endoscopies performed in 2009. The total cost for outpatient gastrointestinal
endoscopy examinations was $32.4 billion.
Conclusions—GI diseases are a source of substantial morbidity, mortality and cost in the US.
Keywords
Epidemiologic analysis; health services; gastrointestinal endoscopy; statistics
Gastrointestinal diseases affect an estimated 60 to 70 million Americans annually.1 In 2004,
there were an estimated 4.6 million hospitalizations, 72 million ambulatory care visits and
236,000 deaths attributable to gastrointestinal disease.1 Spending on gastrointestinal
diseases in the United States has been estimated at $142 billion per year in direct and
indirect costs.1
Current descriptive statistics describing the toll of gastrointestinal diseases are necessary to
guide research, education and resource allocation. Reports detailing the burden of
gastrointestinal disease have been published and are frequently utilized for these
endeavors.1–6 With the availability of recent data and additional resources, an updated report
is needed.
Our objective was to summarize from large national databases the most recent data on
gastrointestinal morbidity, mortality, and cost in adults in the United States. We compiled
the most recent statistics on gastrointestinal symptoms, quality of life, outpatient diagnoses,
hospitalizations, cost, cancer and mortality. Because gastrointestinal endoscopy makes a
major contribution to the diagnosis, management and treatment of most gastrointestinal
symptoms and diseases, we also generated estimates for the current utilization and cost of
gastrointestinal endoscopies in the United States. We assessed trends in endoscopic
utilization and compiled indications for common gastrointestinal endoscopic procedures.
Methods
We compiled the most recently available statistics on gastrointestinal symptoms, quality of
life, outpatient diagnoses, hospitalizations, cost, cancer, mortality and endoscopic utilization
from a variety of publicly- and privately-held databases. We utilized limited data sets with
no direct patient identifiers. Data use agreements were signed as necessary. The methods
used to compile the data from the respective source database are detailed below.
Symptoms and Diagnoses
We tabulated the leading gastrointestinal symptoms and physician gastrointestinal diagnoses
for outpatient clinic visits in the United States from the 2009 National Ambulatory Medical
Care Survey (NAMCS). NAMCS is an annual national survey sponsored by the U.S.
Centers for Disease Control and Prevention (CDC) to provide information about the use of
ambulatory services by children and adults in the United States (http://www.cdc.gov/nchs/
ahcd.htm).
NAMCS collects symptom data with abstraction forms and is based on patient reported
symptoms. We used the principal reason for the clinic visit in our analysis. We combined
related symptoms and created a rank order list. For example, the category “gastrointestinal
bleeding” includes “gastrointestinal bleeding”, “blood in stool”, and “vomiting blood”.
NAMCS also collects physician diagnoses from pediatric and adult patient encounter forms
categorized according to the International Classification of Diseases, 9th Revision (ICD-9).
A maximum of three ICD-9 codes are reported. We used the primary diagnosis for the visit
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unless otherwise noted. We combined related diagnoses and created a rank order list. We
excluded “special screening of malignant neoplasm of the colon” (V765.1, n≈1.6 million
visits) because the code does not represent a diagnosis.
Quality of Life
We report the impact of select gastrointestinal diseases and symptoms on quality of life and
work and activity impairment using the 2010 United States National Health and Wellness
Survey (NHWS) (N=75,000) (Kantar Health, New York, NY, USA). The NHWS is an
annual, cross-sectional study administered by a private company to generate data on health-
related outcomes and patient healthcare attitudes in persons eighteen years and older. The
NHWS utilizes a self-administered, internet-based questionnaire. All participants complete
an in-depth demographic profile and give informed consent. The NHWS uses a stratified
random sample procedure to generate statistics reflective of the demographic composition of
the United States, based on the March 2009 Census Bureau Current Population Survey. The
prevalence estimates of conditions in the NHWS are comparable with the National Heath
Interview Survey, National Health and Nutrition Examination Survey and Medical
Expenditure Panel Survey.7–9
The NHWS assesses health related quality of life with the Medical Outcomes Study 12-item
Short Form Survey Instrument (SF-12)10 and work and activity impairment with the Work
Productivity and Activity Impairment Questionnaire in persons 18 years of age and
older.11, 12 We generated mean SF-12 mental and physical component scores. A lower score
is associated with worse quality of life. We also generated activity and work impairment
scores, which represent the percentage of health-related impairment in daily activities and
work, respectively, in the past seven days. A higher percentage is associated with greater
impairment. Work impairment included only participants who were employed. Participants
with select diseases were identified for these analyses with the question “have you ever been
diagnosed with X disease?” Participants with select symptoms were identified with the
question “have you ever experienced Y symptom?” Reference diseases and symptoms have
been included for comparison. Participants identified as “no disease” denied any of greater
than one hundred listed diseases. Population norms for Mental and Physical Component
Summary scores were derived from the scoring algorithm of the Short Form-12 version 2.
Population norms for the overall work impairment and activity impairment were derived by
taking the mean across the entire NHWS sample (for employed-only respondents and all
respondents, respectively).
Hospitalizations
We compiled the most common inpatient gastroenterology and hepatology discharge
diagnoses from the 2009 Nationwide Inpatient Sample (NIS) (http://www.hcup-us.ahrq.gov/
nisoverview.jsp). NIS was developed as part of the Healthcare Cost and Utilization Project
(HCUP), a Federal-State-Industry partnership sponsored by the Agency for Healthcare
Research and Quality. NIS contains data from approximately 8 million hospital stays each
year in both the pediatric and adult population. NIS is the largest all-payer inpatient care
database in the United States. The 2009 NIS contains all discharge data from 1,050 hospitals
located in 44 States, approximating a 20% stratified sample of Unites States community
hospitals. The sampling frame for the 2009 NIS is a sample of hospitals that comprises
approximately 95% of all hospital discharges in the United States.
We generated rank order lists of discharge diagnoses and procedures for all patients in all
hospitals. The diagnoses and procedures were categorized according to ICD-9 codes. We
identified gastroenterology and hepatology diagnoses from the top 100 discharge diagnoses.
We combined related discharge diagnosis codes. We created a rank order list of principal
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discharge diagnoses. We repeated this process and created a rank order list of any discharge
diagnosis.
Additionally, we identified ICD-9 codes for several important gastroenterology and
hepatology diagnoses not captured among the top 100 discharge diagnoses (ex.
inflammatory bowel disease), and created a separate table of summary statistics for these
diagnoses. Our results include both children and adults.
We performed a separate query for each individual ICD-9 code (or group of codes) to
acquire data on mean and median length of stay (LOS), median costs, aggregate charges,
and deaths. We estimated the total hospital days per year for all persons with each diagnosis
by multiplying the number of discharges by the mean LOS. We performed a temporal
analysis of the most common and select principal GI diagnoses to determine the change in
discharges between 2000 and 2009.
Cancer
We tabulated gastrointestinal cancer incidence, mortality and five-year survival from the
Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer
Institute (www.seer.cancer.gov). The SEER program is a collection of population-based
registries from 18 geographic regions in the United States including nine states, five
metropolitan areas, and the Alaska Native Tumor Registry. The SEER program includes
both children and adults and represents approximately twenty-six percent of the United
States population. We used the most recent version of the SEER Program (April 2011),
which includes survival data through 2007, and incidence data through 2008.
We gathered unadjusted gastrointestinal cancer incidence and mortality rates (per 100,000).
We estimated the annual number of incident cases and deaths using the unadjusted rates,
stratified by gender and age and applied to the 2010 US census population. We gathered
five-year survival data and reported the proportion surviving 5-years after diagnosis and
stratified by stage of disease at diagnosis.
Mortality
We tabulated the leading gastrointestinal causes of death from the National Vital Statistics
System (NVSS) (http://www.cdc.gov/nchs/data_access/Vitalstatsonline.htm). NVSS is
sponsored by National Center for Health Statistics with the Centers for Disease Control and
Prevention. NVSS maintains an annually updated, county-level, national mortality database
of children and adults with causes of death collected and reported by state registries. Causes
of death are derived from death certificates and are classified by ICD-10 code. The most
recent data were available from 2009.
We generated a rank order list of the most common gastrointestinal causes of death. We
combined associated diagnoses to create a single, clinically meaningful entity. For example,
ulcers includes ICD-10 codes for gastric ulcer (K25), duodenal ulcer (K26), peptic ulcer
(K27) and gastrojejunal ulcer (K28). We calculated the crude rate per 100,000 by dividing
the number of deaths listed as an underlying cause by the total US population in the United
States in 2009 (306,272,395) and multiplied by 100,000. The denominator was derived from
population statistics on the CDC’s Wide-ranging Online Data for Epidemiologic Research
(WONDER) website (http://wonder.cdc.gov). We repeated the process and created a rank
order list of deaths from selected liver diseases. Our results include both children and adults.
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We generated an estimate for the prevalence and cost of upper, lower and biliary
endoscopies in 2009 using the Thompson Reuters MarketScan® commercial, Medicare, and
Medicaid databases. These databases contained de-identified, person-level health care
claims data for all inpatient, outpatient, and pharmaceutical services for a selection of health
plans. These databases included both pediatric and adult populations with the exception of
Medicare. Our results include both children and adults. In our analyses limited to 2009, the
total numbers of individuals in each database were 29 million, 2.7 million, and 3.5 million,
respectively.
We used current procedural terminology (CPT) codes to identify all endoscopic procedures
in three broad categories: upper (esophagogastroduodenoscopy (EGD), upper endoscopic
ultrasound (EUS), and enteroscopy), lower (colonoscopy, flexible sigmoidoscopy, lower
endoscopic ultrasound, pouch/stoma endoscopy), and biliary (endoscopic retrograde
cholangiopancreatography (ERCP)). We estimated the number of procedures performed in
the United States in 2009 by standardizing the number of procedures in each database to the
actual age and gender distribution of the U.S. population based on 2009 census data. We
determined the costs of endoscopic procedures in the United States in 2009 by summing all
outpatient expenditures from the day of the procedure standardized by age and gender.
Inpatient endoscopic procedure costs could not be isolated from other hospital-associated
costs and were excluded from this analysis. We performed sub-analyses for common codes
because the upper and lower endoscopy categories encompassed multiple procedures. The
sub-analyses included EGD (diagnostic EGD, CPT 43235; and EGD with biopsy, CPT
43239) and colonoscopy (colonoscopy with biopsy, CPT 45380; and colonoscopy with
polypectomy, CPT 45385).
We examined time trends in procedure volume in the three broad categories detailed above
(upper, lower and biliary) from 2000–2009 in the Thompson Reuters MarketScan®
commercial database.
We also examined time trends for procedures reimbursed by Medicare Part B from 2000 to
2010. Medicare Part B National Summary Data Files are available through the Centers for
Medicare and Medicaid Services (http://www.cms.gov/). We used CPT codes to identify all
endoscopic procedures in 5 categories – upper endoscopy, colonoscopy, endoscopic
retrograde cholangiopancreatography, magnetic resonance cholangiopancreatography, and
upper and lower endoscopic ultrasound. The total number of procedures performed was
calculated for each category annually between 2000 and 2010.
We compiled indications for common gastrointestinal endoscopic procedures between
2005–2010 from the Clinical Outcomes Research Initiative’s (CORI) National Endoscopic
Database (NED). CORI is a consortium of 108 sites from 87 practices. These practices
include an adult population from private practices, academic medical centers, and
government agencies (e.g. military and VA Health Services). Participating sites use a




The leading gastrointestinal symptoms prompting an outpatient clinic visit in 2009 are listed
in Table 1. Abdominal pain is the most common GI symptom with an estimated 15.9 million
visits in 2009. Other leading symptoms at outpatient visits were diarrhea, constipation,
vomiting and nausea.
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The most common physician diagnoses for gastrointestinal disorders in outpatient clinic
visits in 2009 are listed in Table 2. Gastroesophageal reflux was the most frequent outpatient
diagnosis with almost 9 million visits in 2009. Abdominal pain, gastroenteritis and
dyspepsia, constipation, abdominal wall hernia, and diverticular disease followed in
frequency.
Quality of Life
The impact of select gastrointestinal diseases and symptoms on quality of life, overall work
productivity and activity impairment are detailed in Supplementary Table 1. In all diseases
and symptoms for all outcomes except colorectal cancer, we found worse quality of life and
significantly more work and activity impairments compared to population norms. In this
survey, participants with a history of colorectal cancer are likely to be cancer survivors and
these individuals demonstrate better mental health, but worse physical health, than
population norms.
Hospitalizations
The most common inpatient principal gastrointestinal discharge diagnoses from 2009 are
detailed in Table 3. Acute pancreatitis was the most common single gastrointestinal
diagnosis and cost an estimated 2.6 billion dollars per year in inpatient costs. Combined
diverticular disease (diverticulitis and hemorrhage) was actually more common than acute
pancreatitis and also cost an estimated 2.6 billion dollars per year. Clostridium difficile
infection discharges increased 237% since 2000 and account for a proportion of inpatient
mortality similar to gastrointestinal hemorrhage (Figure 1. Panel A).
Statistics for select gastrointestinal and hepatology related discharge diagnoses not among
the top 100 discharge diagnoses are detailed in Table 3. Chronic liver disease and viral
hepatitis was associated with 6% mortality and cost an estimated $1.8 billion per year in
inpatient cost. Hospitalizations for nonalcoholic fatty liver disease have increased 97% since
2000. Inflammatory bowel disease and functional/motility disease both cost almost $1
billion per year in inpatient costs.
The most common inpatient gastrointestinal and hepatology related discharge diagnoses
among any listed diagnoses from 2009 are detailed in Supplementary Table 2. Esophageal
reflux (4.4 million), obesity (1.7 million) and constipation (1 million) were the most
common discharge diagnoses.
Cancer
Gastrointestinal cancer incidence, mortality, and five-year survival are detailed in Table 4.
An estimated 147,308 people were diagnosed with colorectal cancer in the United States in
2008. When diagnosed with localized disease, five-year survival is 90%. Esophageal,
pancreatic and liver cancer are less common but are associated with five-year survival of
less than 40% even when diagnosed at an early stage.
Mortality
In 2009, there were a total of 2,437,163 deaths in the United States with 245,921 attributable
to an underlying gastrointestinal cause (10%). The leading gastrointestinal causes of death
are presented in Table 5. Colorectal cancer remains the leading gastrointestinal cause of
mortality followed by pancreatic and hepatobiliary neoplasms. Clostridium difficile is now
the 9th leading gastrointestinal cause of death, increasing from 2,195 deaths in 2002 to 7,251
in 2009, a 230% absolute increase.
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In 2009, there were 30,558 deaths in the United States attributed to chronic liver disease and
cirrhosis, representing the 12th leading cause overall. Malignant neoplasms of the liver and
biliary tree represent the most frequent cause of hepatic and biliary mortality, followed by
cirrhosis/fibrosis, alcoholic liver disease, and chronic hepatitis C virus infection (Table 5).
Mortality rates associated with each of these causes of death have increased since 2002,
whereas the rates attributable to acute and chronic hepatitis B and primary biliary cirrhosis
have remained stable.
Endoscopic Utilization
There were an estimated 6.9 million upper, 11.5 million lower, and 228,000 biliary
endoscopies performed in the United States in 2009 based on Thompson Reuters
MarketScan® commercial, Medicare, and Medicaid databases. The estimated total outpatient
cost was $32.4 billion. Upper endoscopies were estimated at $12.3 billion, lower
endoscopies $19.2 billion and ERCP $900 million. The estimated average costs for all upper
endoscopies, lower endoscopies, and ERCPs were $1,775, 1,672, and $3,899, respectively.
The estimated average total cost for EGD alone (either diagnostic or with biopsy) was $685.
The estimated average total cost for colonoscopy alone (either with biopsy or with
polypectomy) was $1,013.
The trends in endoscopic volume in commercially insured patients in the United States
between 2000 and 2009 are detailed in Figure 2 Panel B. We found a 54% and 17% increase
in all upper and lower GI endoscopy, respectively, but a 16% decrease in ERCP.
Additionally, the trends in endoscopic volume in Medicare Part B in the United States
between 2000 and 2010 are detailed in Table 6. Overall, there was also a significant increase
in the performance of endoscopic procedures in Medicare recipients over the last decade.
Colonoscopy is consistently the most commonly performed procedure with over 3.3 million
colonoscopies performed in Medicare beneficiaries in 2010. While the use of MRCP was
significantly lower than that of ERCP in 2000, there has been a nearly 8-fold increase in its
use, making it more than twice as common as ERCP in 2010. EUS utilization has increased
6-fold in the last ten years.
A total of 785,302 colonoscopies, 34,884 flexible sigmoidoscopies, 448,888 EGDs, 16,980
ERCPs, and 13,374 EUSs were recorded in CORI-NED from 2005–2010. The most
common indications for upper endoscopy were reflux symptoms (24%), dysphagia (20%),
evaluation for any GI bleeding symptom (19%), and abdominal pain or bloating (18%)
(Supplementary Table 3). The most common indications for colonoscopy were routine
screening exams (32%), evaluation of any GI bleeding symptom (22%), and surveillance for
adenomatous polyps (18%) (Supplementary Table 4).
Discussion
As detailed above, the toll of gastrointestinal and liver disease on the U.S. population is
extensive. Using the most comprehensive statistical resources available, we present a broad
and detailed picture of the current challenges facing these patients and our specialty. Several
trends merit special mention.
The toll of C. difficile infection is large and becoming more prominent. C. difficile
hospitalizations have increased by 237% since 2000. This finding is consistent with the
documented increase in C. difficile incidence in the United States.13–15 In-hospital mortality
attributable to C. difficile is estimated at 4%, which is comparable to the 30 day estimate of
6%.16 C. difficile is now the 9th leading gastrointestinal cause of death.
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We also found that C. difficile infection was associated with marked impairment in quality
of life and capacity for activity. These data may actually represent an under-estimate of the
association of this infection with diminished quality of life, given that some proportion of
the participants in the NHWS had resolved disease. Whether those with resolved disease
also have impaired quality of life and activity impairment is unknown.
Hospitalizations for morbid obesity increased by 314% since 2000. While the prevalence of
obesity between 1998 and 2008 was relatively stable, the prevalence of morbid obesity has
increased significantly.17 Bariatric surgical procedures also increased, from 13,000 in 1998
to more than 100,000 in 2003, and this may account for some portion of the observed
trend.18
Reflux symptoms remain the most common indication for upper endoscopy, and
gastroesophageal reflux disease the most common principal gastroenterology-related
diagnosis in the primary care setting. Barrett’s esophagus accounted for almost a half
million visits in 2009. An estimated 3.3 million Americans have a diagnosis of Barrett’s
esophagus.19 Most (90%) patients with Barrett’s esophagus have nondysplastic disease.20
Guidelines generally recommend that patients with nondysplastic disease undergo
endoscopic surveillance every three to five years. Given the large number of subjects with
Barrett’s, these examinations represent a substantial commitment of resources.
An estimated 147,308 people were diagnosed with colorectal cancer in the United States in
2008. Colorectal cancer continues to be the number one cause of GI-related mortality.
Colorectal cancer accounts for more than half of all GI cancer diagnoses and a third of GI
cancer-related deaths.
There is no single national endoscopic database to estimate the prevalence and cost of
endoscopy. We generated our estimates using a mix of public and private databases. Total
outpatient cost for gastrointestinal endoscopy in 2009 was $32.4 billion. Our estimate is
higher than a previous estimate1 and suggests that the cost of gastrointestinal endoscopy is
not well characterized. Our estimate is likely a more accurate approximation because we
utilized health care claims data from 35 million people in a mix of public and private
databases and standardized the estimates of procedures performed to the US population
based on census data.
We estimated that 6.9 million upper, 11.5 million lower, and 228,000 biliary endoscopies
were performed in the United States in 2009. A survey published in 2000 estimated that 5
million flexible sigmoidoscopies and 4 million colonoscopies were performed that year in
the United States.21 A second survey in 2002 estimated that approximately 2.8 million
flexible sigmoidoscopies and 14.2 million colonoscopies were performed.22 No recent
estimates on upper endoscopies or biliary endoscopies have been published. Our data
demonstrate that ERCP volume has increased more slowly than that of other endoscopic
procedures. Concurrently, the use of MRCP has increased dramatically, perhaps due to the
expanded role of MRCP in the diagnosis of pancreaticobiliary disorders and the decreased
use of ERCP for purely diagnostic indications.
Our findings should be viewed in light of the strengths and limitations of the databases from
which we gathered the data. NAMCS data are based on office-based physician visits and do
not reflect other important sources of ambulatory care including the emergency department,
urgent care and federal facilities. The strength of NAMCS is that the diagnoses and patient
symptoms are extracted from the medical record using a standardized procedure. The
NHWS is an Internet based survey. Diagnoses are not verified and it is possible that those
who respond are systematically different then those who do not complete the survey.
Despite these limitations, NHWS is a large nationally representative sample comparable
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with the National Heath Interview Survey.7 Not all states contribute to NIS. Cost estimates
are approximated from charges and do not include physician fees. Regardless, NIS is the
largest all-payer inpatient data source in the United States and contains charge information
on all patients. SEER data represents 18 areas of the country. While the data are weighted to
approximate national estimates they are not statistically representative. SEER data are
verified and data are estimated to be 99 percent complete from contributing sites. The
National Vital Statistics System is a complete accounting of deaths in the United States but
is dependent on the accuracy of death certificates, and coding of death certificates may be
erroneous. Inpatient endoscopic procedure costs could not be isolated from other hospital-
associated costs and were excluded from this analysis. CORI data are based on voluntary
participation and are not nationally representative. . Finally, our ability to detect conditions
that cause substantial burden of disease depends on codes that may be imprecise, poorly
used, or non-existent. Non-alcoholic fatty liver disease, for example, is prevalent but is
newly recognized and therefore poorly captured with codes. For this reason, updated reports
will be needed as more recent data becomes available.
In summary, we present a comprehensive and current estimate of the toll of gastrointestinal
and liver diseases in the U.S. Payers, policymakers, clinicians, and others interested in
resource utilization may use these statistics to better understand evolving disease trends, and
the best way to meet the challenge of these diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Panel A: Number of annual hospital discharges with a principal diagnosis of C. difficile
infection, 1993–2009, from the National Inpatient Sample
Figure 1. Panel B: Time trends in endoscopy procedure rates in commercially insured
patients in the United States, 2000–2009. Upper GI endoscopy included
esophagogastroduodenoscopy, upper endoscopic ultrasound, and enteroscopy. Lower GI
endoscopy included colonoscopy, flexible sigmoidoscopy, lower endoscopic ultrasound, and
pouch/stoma endoscopy.
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Table 1









6 Heartburn and indigestion 1,982,517
7 Rectal bleeding 1,702,331
8 Other GI symptoms, unspecified 1,357,602
9 Dysphagia 1,148,041
10 Gastrointestinal bleeding 1,073,771
11 Appetite decrease 725,705
12 Bloating and distention 699,928
13 Anorectal symptoms (including incontinence) 520,772
14 Symptoms related to the liver and biliary system 454,355
*
2009 National Ambulatory Medical Care Survey (http://www.cdc.gov/nchs/ahcd.htm).
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Table 2
Leading Physician Diagnoses for Gastrointestinal Disorders in Outpatient Clinic Visits in the United States,
2009*
Rank Diagnosis Estimated visits ICD-9 Codes
1 GERD† 8,863,568 530.11, 530.81
2 Abdominal pain 7,170,332 389.04, 789.00, 789.06, 789.07, 789.09
3 Gastroenteritis and dyspepsia 4,007,198 008.8, 535.50, 536.8
4 Constipation 3,980,438 564.00
5 Abdominal wall hernia 3,559,932 550.90, 553.10, 553.20
6 Diverticular disease 2,682,168 562.10, 562.11
7 Diarrhea 2,402,350 787.91
8 Inflammatory bowel disease 1,893,799 555.9, 556.9
9 Colorectal neoplasm 1,744,089 153.9, 154.0, 154.1, 211.3
10 Nausea and vomiting 1,678,515 787.02, 787.03
11 Rectal bleeding 1,667,653 569.3, 578.1
12 Irritable colon 1,550,072 564.1
13 Hepatitis C infection 1,230,420 070.54, 070.70
14 Hemorrhoids 1,071,430 455.0, 455.4, 455.6, 455.8
15 Dysphagia 1,020,743 787.20
16 Appendicitis 663,930 541.0
17 Cirrhosis of liver 635,463 571.5
18 Barrett s esophagus 440,605 530.85
19 Hepatitis, unspecified 379,062 573.3
20 Gallstone disease 303,606 547.10
*
2009 National Ambulatory Medical Care Survey (http://www.cdc.gov/nchs/ahcd.htm).
†
GERD also includes visits with a primary diagnosis of diaphragmatic hernia (553.3) and a secondary diagnosis code of Esophageal reflux
(530.81).
‡
Gastroenteritis and dyspepsia also includes visits with a primary diagnosis of diaphragmatic hernia (553.3), but without a secondary diagnosis
code of Esophageal reflux (530.81).
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